Kanishk Kumar on 2034 Forecasts for aHUS Associated Thrombotic Microangiopathy
Kanishk Kumar, Digital Marketing Executive at DelveInsight Business Research LLP, shared on LinkedIn:
”Atypical Hemolytic Uremic Syndrome Market 2034: Targeting Complement-Mediated Thrombotic Microangiopathy
Atypical Hemolytic Uremic Syndrome (aHUS), a rare thrombotic microangiopathy caused by uncontrolled complement activation, is advancing with novel C5 inhibitors and factor B blockers in 2034.
Delve Insight‘s report covers epidemiology in the 7MM (US, EU4, UK, Japan), market dynamics, and forecasts, projecting significant CAGR from 2020-2034, with ~4,800 diagnosed cases in 7MM in 2023, ~3,500 in US, and adolescents/adults representing ~80% of cases.
Key Developments in aHUS Market:
December 11, 2025: Novartis launched a Phase 3 study of iptacopan in treatment-naive aHUS patients.
December 8, 2025: Alexion Pharmaceuticals, Inc. disclosed a Phase 3b study of eculizumab in Chinese aHUS patients.
Leading Atypical Hemolytic Uremic Syndrome Companies include Novartis, Hoffmann-La Roche, Chugai Pharmaceutical Co., Ltd., Alexion Pharmaceuticals, Inc. , and others.
Promising therapies include Eculizumab, Crovalimab, Iptacopan, NM8074, Ravulizumab, ULTOMIRIS, SOLIRIS, and others.
Delve Insight’s comprehensive report on Atypical Hemolytic Uremic Syndrome Market Insights, Epidemiology and Market Forecast – 2034”
Find the full report here.
Read the full post.
Stay updated with Hemostasis Today.
-
May 24, 2026, 17:48Flora Peyvandi: Crucial Role of Placental ADAMTS13 in Perinatal Survival
-
May 24, 2026, 17:13Mahtab Mashayekhi: The Evolving Role of Red Blood Cell Exchange in the Management of SCD
-
May 24, 2026, 17:12Silvina Graña: Helping Families Better Understand Hemophilia and Daily Life With Bleeding Disorders
-
May 24, 2026, 17:11Miikka Vikkula: Key Insights from the ISSVA 2026 World Congress
-
May 24, 2026, 17:10Mathieu Jackson: Proud to Be Present at This Historic Moment for the Global Bleeding Disorders Community
-
May 24, 2026, 17:09Ramina Fazeli: Highlighting the Emerging Role of Neutrophil Extracellular Traps in Ovarian Cancer
-
May 24, 2026, 16:12William Wallace: Normal B12 Levels May Still Cause Brain Damage and Cognitive Decline
-
May 24, 2026, 15:54Marc Carrier: Ottawa Race Weekend Raised Over 7,000 USD for Thrombosis Canada
-
May 24, 2026, 15:44Janak Sadhu: Building a Stroke-Free Mehsana Through Community Awareness and Healthcare Collaboration